HTA and cell and gene remedy – Healthcare Economist

A paper by Drummond et al. (2023) examines how Health Technology evaluation our bodies cope with the problem of worth evaluation for cell and gene therapies (often known as Superior Remedy Medicinal Merchandise (ATMPs) in Europe). To do that the authors:

…undertook i) a focused overview of the literature on the medical and financial proof wants for these therapies, and ii) an in-depth evaluation of HTA studies from 8 main jurisdictions for 9 cell and gene therapies in 10 indications, along with any related publicly obtainable paperwork on managed entry agreements and post-launch proof necessities.

The authors used a knowledge extraction kind from Drummond et al. (2019).

The authors study these components and decide the share of which these components have been cited in a optimistic, adverse or impartial method.

Additionally of curiosity is that whereas some broader or societal worth components have been cited in ATMP worth evaluation, this was removed from ubiquitous.

The paper is fascinating all through and you’ll learn the complete paper here.